Supplementary Data — Ribavirin for hantavirus: real-time meta-analysis of 3 studies

@CovidAnalysis, May 2026, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huggins (DB RCT) 74% 0.26 [0.07-0.93] death 3/122 10/107 HFRS, Hantaan Improvement, RR [CI] Treatment Control Huggins (DB RCT) 74% 0.26 [0.07-0.93] death 3/122 10/107 HFRS, Hantaan Huggins (DB RCT) 84% 0.16 [0.03-0.85] death 3/122 10/107 HFRS, Hantaan Huggins (DB RCT) 73% 0.27 [0.10-0.73] progression 122 (n) 107 (n) HFRS, Hantaan Malinin (RCT) 67% 0.33 [0.01-7.85] progression 0/37 1/36 HFRS, Puumala Malinin (RCT) -17% 1.17 [1.01-1.36] progression 37 (n) 36 (n) HFRS, Puumala Malinin (RCT) -15% 1.15 [0.97-1.38] viral time 37 (n) 36 (n) HFRS, Puumala Mertz (DB RCT) -30% 1.30 [0.22-7.69] death 2/10 2/13 HCPS, Sin Nombre Mertz (DB RCT) 22% 0.78 [0.24-2.51] progression 3/10 5/13 HCPS, Sin Nombre Ribavirin hantavirus outcomes c19early.org May 2026 Favors ribavirin Favors control
Fig. S1. All outcomes.